Benjamin M Kagina1, Nazma Mansoor2, Eloi P Kpamegan3, Adam Penn-Nicholson4, Elisa Nemes4, Erica Smit4, Sebastian Gelderbloem5, Andreia P Soares6, Brian Abel7, Alana Keyser4, Mzwandile Sidibana4, Jane E Hughes4, Gilla Kaplan8, Gregory D Hussey1, Willem A Hanekom4, Thomas J Scriba9. 1. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Vaccines for Africa Initiative, Division of Medical Microbiology & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa. 2. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; BD Biosciences, Johannesburg, South Africa. 3. Aeras, Rockville, MD, USA. 4. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa. 5. Aeras, Cape Town, South Africa. 6. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa. 7. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore. 8. Public Health Research Institute, NJMS Rutgers, Newark, NJ, USA; Bill & Melinda Gates Foundation, Seattle, WA, USA. 9. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa. Electronic address: thomas.scriba@uct.ac.za.
Abstract
BACKGROUND: Qualified or validated assays are essential in clinical trials. Short-term stimulation of whole blood and intracellular cytokine staining assay is commonly used to measure immunogenicity in tuberculosis vaccine clinical trials. Previously, the short-term stimulation process of whole blood with BCG was optimized. We aimed to qualify the intracellular cytokine staining process and assess the effects of long-term cryopreservation. Our hypotheses were that the assay is robust in the measurement of the mycobacteria-specific T cells, and long-term cryopreservation of fixed cells from stimulated whole blood would not compromise reliable measurement of mycobacteria induced CD4 T cell immunity. METHODS: Whole blood from healthy adults was collected in sodium heparinized tubes. The blood was left unstimulated or stimulated with mycobacterial antigens or mitogens for 12h. Cells were harvested, fixed and multiple aliquots from each participant cryopreserved. Later, mycobacteria-specific CD4 and CD8 T cells expressing IFN-γ, TNF-α, IL-2 and IL-17 were quantitated by flow cytometry. Assay performance characteristics evaluated included limit of quantification and detection, reproducibility, precision, robustness, specificity and sensitivity. To assess the effects of long-term cryopreservation, fixed cells from the stimulated bloods were analysed one week post-cryopreservation and at 3-month intervals over a 3-year period. RESULTS: The limit of quantification for the different cytokines was variable: 0.04% for frequencies of IFN-γ- and IL-2-expressing T cells and less than 0.01% for TNF-α- and IL-17-expressing T cells. When measurement of the mycobacteria-specific T cells was assessed at levels above the detection limit, the whole blood intracellular cytokine assay showed high precision that was operator-independent. The assay was also robust: variation in staining conditions including temperature (4 °C or 20-23 °C) and time (45, 60 or 90 min) did not markedly affect quantification of specific T cells. Finally, prolonged periods of cryopreservation also did not significantly influence quantification of mycobacteria-specific CD4 T cells. CONCLUSIONS: The whole blood intracellular cytokine assay is robust and reliable in quantification of the mycobacteria-specific T cells and is not significantly affected by cryopreservation of fixed cells.
BACKGROUND: Qualified or validated assays are essential in clinical trials. Short-term stimulation of whole blood and intracellular cytokine staining assay is commonly used to measure immunogenicity in tuberculosis vaccine clinical trials. Previously, the short-term stimulation process of whole blood with BCG was optimized. We aimed to qualify the intracellular cytokine staining process and assess the effects of long-term cryopreservation. Our hypotheses were that the assay is robust in the measurement of the mycobacteria-specific T cells, and long-term cryopreservation of fixed cells from stimulated whole blood would not compromise reliable measurement of mycobacteria induced CD4 T cell immunity. METHODS: Whole blood from healthy adults was collected in sodium heparinized tubes. The blood was left unstimulated or stimulated with mycobacterial antigens or mitogens for 12h. Cells were harvested, fixed and multiple aliquots from each participant cryopreserved. Later, mycobacteria-specific CD4 and CD8 T cells expressing IFN-γ, TNF-α, IL-2 and IL-17 were quantitated by flow cytometry. Assay performance characteristics evaluated included limit of quantification and detection, reproducibility, precision, robustness, specificity and sensitivity. To assess the effects of long-term cryopreservation, fixed cells from the stimulated bloods were analysed one week post-cryopreservation and at 3-month intervals over a 3-year period. RESULTS: The limit of quantification for the different cytokines was variable: 0.04% for frequencies of IFN-γ- and IL-2-expressing T cells and less than 0.01% for TNF-α- and IL-17-expressing T cells. When measurement of the mycobacteria-specific T cells was assessed at levels above the detection limit, the whole blood intracellular cytokine assay showed high precision that was operator-independent. The assay was also robust: variation in staining conditions including temperature (4 °C or 20-23 °C) and time (45, 60 or 90 min) did not markedly affect quantification of specific T cells. Finally, prolonged periods of cryopreservation also did not significantly influence quantification of mycobacteria-specific CD4 T cells. CONCLUSIONS: The whole blood intracellular cytokine assay is robust and reliable in quantification of the mycobacteria-specific T cells and is not significantly affected by cryopreservation of fixed cells.
Authors: Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed Journal: Am J Respir Crit Care Med Date: 2012-01-26 Impact factor: 21.405
Authors: Willem A Hanekom; Jane Hughes; Maushumi Mavinkurve; Megan Mendillo; Marcia Watkins; Hoyam Gamieldien; Sebastian J Gelderbloem; Mzwandile Sidibana; Nazma Mansoor; Virginia Davids; Rose Ann Murray; Anthony Hawkridge; Patrick A J Haslett; Stanley Ress; Gregory D Hussey; Gilla Kaplan Journal: J Immunol Methods Date: 2004-08 Impact factor: 2.303
Authors: Cheryl L Day; Michele Tameris; Nazma Mansoor; Michele van Rooyen; Marwou de Kock; Hennie Geldenhuys; Mzwandile Erasmus; Lebohang Makhethe; E Jane Hughes; Sebastian Gelderbloem; Anne Bollaerts; Patricia Bourguignon; Joe Cohen; Marie-Ange Demoitié; Pascal Mettens; Philippe Moris; Jerald C Sadoff; Anthony Hawkridge; Gregory D Hussey; Hassan Mahomed; Opokua Ofori-Anyinam; Willem A Hanekom Journal: Am J Respir Crit Care Med Date: 2013-08-15 Impact factor: 21.405
Authors: Martin O C Ota; Aderonke A Odutola; Patrick K Owiafe; Simon Donkor; Olumuyiwa A Owolabi; Nathaniel J Brittain; Nicola Williams; Sarah Rowland-Jones; Adrian V S Hill; Richard A Adegbola; Helen McShane Journal: Sci Transl Med Date: 2011-06-22 Impact factor: 17.956
Authors: Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane Journal: Lancet Date: 2013-03-23 Impact factor: 79.321
Authors: Albanus O Moguche; Munyaradzi Musvosvi; Adam Penn-Nicholson; Courtney R Plumlee; Helen Mearns; Hennie Geldenhuys; Erica Smit; Deborah Abrahams; Virginie Rozot; One Dintwe; Søren T Hoff; Ingrid Kromann; Morten Ruhwald; Peter Bang; Ryan P Larson; Shahin Shafiani; Shuyi Ma; David R Sherman; Alessandro Sette; Cecilia S Lindestam Arlehamn; Denise M McKinney; Holden Maecker; Willem A Hanekom; Mark Hatherill; Peter Andersen; Thomas J Scriba; Kevin B Urdahl Journal: Cell Host Microbe Date: 2017-06-14 Impact factor: 21.023
Authors: Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam Journal: JCI Insight Date: 2019-12-19
Authors: Matthew D Martin; Isaac J Jensen; Andrew S Ishizuka; Mitchell Lefebvre; Qiang Shan; Hai-Hui Xue; John T Harty; Robert A Seder; Vladimir P Badovinac Journal: J Clin Invest Date: 2019-06-20 Impact factor: 19.456
Authors: Dhanasekaran Sivakumaran; Gretta Blatner; Rasmus Bakken; David Hokey; Christian Ritz; Synne Jenum; Harleen M S Grewal Journal: Front Immunol Date: 2021-06-11 Impact factor: 7.561
Authors: Richard Baguma; Adam Penn-Nicholson; Erica Smit; Mzwandile Erasmus; Jonathan Day; Lebohang Makhethe; Marwou de Kock; E Jane Hughes; Michele van Rooyen; Bernadette Pienaar; Lynnett Stone; Willem Hanekom; Michael J Brennan; Robert S Wallis; Mark Hatherill; Thomas J Scriba Journal: PLoS One Date: 2017-09-08 Impact factor: 3.240